Core Viewpoint - The market for Succinic Acid Metoprolol Sustained-Release Tablets is experiencing a decline in sales due to price reductions from centralized procurement, despite a growing demand driven by an aging population and increasing prevalence of cardiovascular diseases [1][6]. Overview - Succinic Acid Metoprolol Sustained-Release Tablets are a β1 receptor blocker developed by AstraZeneca, primarily used for treating hypertension and chronic heart failure [2]. - The drug is recommended in various hypertension treatment guidelines and is known for its long-lasting effects and improved patient compliance due to its once-daily dosing [2]. Market Policy - The pharmaceutical manufacturing industry, including Succinic Acid Metoprolol, is supported by national policies aimed at encouraging development and reforming the healthcare system [3][4]. Industry Chain - The industry chain includes upstream suppliers of raw materials and excipients, midstream manufacturers involved in research and production, and downstream distribution channels such as healthcare institutions and pharmacies [4]. Current Development - The prevalence of hypertension in China is projected to reach 370 million by 2025, indicating a steady increase in demand for Succinic Acid Metoprolol [6]. - Sales figures show a decline from 3.23 billion yuan in 2022 to an expected 2.39 billion yuan in 2024, with 1.37 billion yuan recorded in the first half of 2025 [1][6]. Competitive Landscape - AstraZeneca holds a significant market share of 63.8% in 2024, indicating substantial room for domestic companies to capture market share [8]. - Domestic companies like Hefei Heyuan Pharmaceutical and Nantong Lianya Pharmaceutical are emerging players, with Lianya's sales of Succinic Acid Metoprolol reaching 240 million yuan in the first half of 2025 [8][9]. Development Trends - The industry is expected to undergo structural changes driven by policy reforms, shifting from price competition to value competition, and focusing on product quality and safety [10][11]. - The demand for Succinic Acid Metoprolol is anticipated to grow due to an aging population and increased health awareness, with a focus on long-acting and convenient medications [11]. - Technological innovations in sustained-release formulations and cost-effective production methods are expected to enhance product competitiveness and meet diverse clinical needs [12].

Group 1 - The core point of the article is the resignation of Zheng Zhonghui, the Deputy General Manager of XinHua Pharmaceutical, due to personal reasons, effective September 5, 2025 [1] - XinHua Pharmaceutical's revenue composition for the first half of 2025 is as follows: 44.36% from chemical drug formulation manufacturing, 32.11% from chemical raw material manufacturing, and 23.53% from pharmaceutical intermediates and others [1] - As of the report, XinHua Pharmaceutical has a market capitalization of 11.4 billion yuan [1]

Core Insights - Xinhua Pharmaceutical's revenue composition for 2024 is as follows: 48.1% from chemical drug formulation manufacturing, 32.32% from chemical raw material manufacturing, and 19.59% from pharmaceutical intermediates and others [1]. Group 1 - Xinhua Pharmaceutical announced the approval of Finasteride tablets by the National Medical Products Administration [3]. - The product name for the newly approved drug is "Finasteride Tablets" [3].

上海小方制药股份有限公司 Shanghai Xiao Fang Pharmaceutical Co.,Ltd. （发行人地址：上海市奉贤区洪朱路 777 号） 首次公开发行股票并在主板上市招股说明书 保荐人（主承销商） （注册稿） （地址：深圳市罗湖区红岭中路 1012 号国信证券大厦十六至二十六层） 上海小方制药股份有限公司 招股说明书（注册稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 上海小方制药股份有限公司 招股说明书（注册稿） 本次发行概况 本公司的发行申请尚需经交易所和中国证监会履行相应程序。本招股说明书 不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当以正 ...

上海小方制药股 Shanghai Xiao Fang Pharr td. (发行人地址:上海市奉贤区洪朱路 777 号) 点小方制药 首次公开发行股票并在主板上市招股说明书 (上会稿) 保荐人(主承销商) 国信证券股份有限公司 GUOSEN SECURITIES CO.,LTD. (地址:深圳市罗湖区红岭中路1012 号国信证券大厦十六至二十六层) 上海小方制药股份有限公司 招股说明书（上会稿） 重要声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 上海小方制药股份有限公司 招股说明书（上会稿） 本次发行概况 本公司的发行申请尚需经交易所和中国证监会履行相应程序。本招股说明书 不具有据以发行 ...